Indonesian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Halaman 1 dari 188 hasil
Estimating the Quantitative Demand of NOAC Antidote Doses on Stroke Units.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
The first specific antidote for non-vitamin K antagonist oral anticoagulants (NOAC) has recently been approved. NOAC antidotes will allow specific treatment for 2 hitherto problematic patient groups: patients with oral anticoagulant therapy (OAT)-associated intracerebral hemorrhage (ICH) and maybe
Ancrod--is snake venom an antidote for stroke?
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Anticoagulation for stroke prevention in atrial fibrillation (AF) is effective. Pivotal trials RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE-AF TIMI 48 tested novel agents against warfarin (W). In RE-LY, an open-label trial, dabigatran 150 mg BID (D150) was superior (35%) and 110 mg BID (D110) was
Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis. Officially authorized Japanese guidelines on this issue were revised twice at the time of
[New oral anticoagulants (NOAC) in stroke treatment].
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Since 2011, new oral anticoagulants (NOAC) can be prescribed for prevention of cardio-embolic ischemic strokes in addition to vitamin K antagonists. NOAC are indicated in patients with non-valvular atrial fibrillation. Although its use is a matter of debate in Germany, the neurological and
[New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
New oral anticoagulants for the prevention of stroke in patients with nonvalvular atrial fibrillation have been available for a few months, among them the reversible direct thrombin inhibitor dabigatran and the factor Xa antagonist rivaroxaban. These drugs are considered by some as a superior
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
OBJECTIVE
To evaluate the safety and efficacy of dabigatran for stroke prevention in the elderly population.
METHODS
MEDLINE (1948-June 2013), Web of Science (1980-June 2013), and Google Scholar were used to identify relevant literature. Search terms included dabigatran, dabigatran etexilate,
New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and
Newer clinically available antithrombotics and their antidotes.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
New oral anticoagulants (NOACs) have emerged as an alternative therapy to warfarin in the treatment of arterial and venous thromboembolism and in stroke prevention in patients with non-valvular atrial fibrillation (AF). Three of them, i.e., dabigatran, rivaroxaban, and apixaban, have been approved
Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Dabigatran etexilate is an oral, reversible direct thrombin inhibitor and has been recently approved for the prevention of stroke in patients with non-valvular atrial fibrillation. This review describes the incidence and management of stroke and related complications in patients on dabigatran
Stroke prevention in atrial fibrillation – latest guideline recommendations and real world data.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Atrial fibrillation (AF) occurs with a prevalence of 1 % in the general population, up to 8 % in patients over 80 years of age and can lead to palpitations, tachycardia, hospitalization for heart failure and stroke. In order to prevent strokes, oral anticoagulation is necessary. In the 2016
Recent advances in the development of specific antidotes for target-specific oral anticoagulants.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Warfarin, a vitamin K antagonist, has been the only orally available anticoagulant for > 60 years. During the past decade, the U.S. Food and Drug Administration has approved several target-specific oral anticoagulants (TSOACs) for the prophylaxis and treatment of arterial and venous thromboembolism
Antidotes for the direct oral anticoagulants: What news?
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
The direct oral anticoagulants (DOACs) are recommended as the first-choice anticoagulants for both stroke prevention in patients with non-valvular atrial fibrillation and the treatment and secondary prevention of venous thromboembolism. DOACs cause bleeding, albeit less than warfarin. Most bleeding
Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab: A Case Report.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Dabigatran etexilate is a direct oral anticoagulant used for the prevention of stroke in atrial fibrillation. Idarucizumab is a recently approved specific antidote that reverses the effect of dabigatran within minutes. We report the case of an 82-year-old patient with traumatic retroperitoneal
Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Thrombotic disorders and their common clinical phenotypes of acute myocardial infarction, ischemic stroke, and venous thromboembolism are the proximate cause of substantial morbidity, mortality, and health care expenditures worldwide. Accordingly, therapies designed to attenuate thrombus initiation
Database tanaman obat terlengkap yang didukung oleh sains
- Bekerja dalam 55 bahasa
- Pengobatan herbal didukung oleh sains
- Pengenalan herbal melalui gambar
- Peta GPS interaktif - beri tag herba di lokasi (segera hadir)
- Baca publikasi ilmiah yang terkait dengan pencarian Anda
- Cari tanaman obat berdasarkan efeknya
- Atur minat Anda dan ikuti perkembangan berita, uji klinis, dan paten
Ketikkan gejala atau penyakit dan baca tentang jamu yang mungkin membantu, ketik jamu dan lihat penyakit dan gejala yang digunakan untuk melawannya.
* Semua informasi didasarkan pada penelitian ilmiah yang dipublikasikan
